Our finding confirms previous conclusions that the therapeutic value of selegiline in the treatment of Parkinson’s disease may be dual, and the dopaminergic enhancer activity of this drug is complementary to its B-type MAO inhibitory effect [30]. Here, SGCG is linked to Parkinson disease.